A muscle protein may signal nerve damage in diabetes — study puts it to the test

NCT ID NCT07734597

Not yet recruiting Knowledge-focused Sponsor: GÜLDEN ANATACA Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This study investigates whether blood levels of irisin, a protein linked to glucose metabolism and nerve protection, differ in people with type 2 diabetes who have diabetic polyneuropathy (nerve damage) compared to those without it and healthy controls. Researchers will measure irisin in fasting blood samples from 81 participants. The goal is to see if irisin could serve as a biomarker to help identify or monitor this common diabetes complication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If irisin levels differ between groups, it could point toward a simple blood test to help detect or monitor diabetic nerve damage.
What could go wrong: This is a small observational study, not a treatment trial. Even if irisin correlates with neuropathy, it may not prove useful as a practical biomarker.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic neuropathy diabetic polyneuropathy polyneuropathy type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2 DIABETIC COMPLICATIONS NEUROLOGICAL POLYNEUROPATHIES

Contacts and locations

Locations

Kanuni Sultan Süleyman Training and Research Hospital

Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.